EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Truist has downgraded Merck (NYSE:MRK) to hold from buy, citing upcoming loss of market exclusivity and continuing headwinds ...

Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

Through its U.S. and Canada life science business MilliporeSigma, Merck KGaA is acquiring Dutch company HUB Organoids. The deal is expected to be finalized by the end of 2024, according to a Dec ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...